250 related articles for article (PubMed ID: 23319695)
21. Pazopanib as third line therapy for metastatic renal cell carcinoma: clinical efficacy and temporal analysis of cytokine profile.
Pal SK; Hossain DM; Zhang Q; Frankel PH; Jones JO; Carmichael C; Ruel C; Lau C; Kortylewski M
J Urol; 2015 Apr; 193(4):1114-21. PubMed ID: 25286010
[TBL] [Abstract][Full Text] [Related]
22. Chromophobe renal cell carcinoma with sarcomatoid dedifferentiation treated with pazopanib: a case report.
Matrana MR; Ng C; Rao P; Lim ZD; Tannir NM
Clin Genitourin Cancer; 2011 Dec; 9(2):137-9. PubMed ID: 21831725
[No Abstract] [Full Text] [Related]
23. Everolimus and pazopanib: two new drugs for renal cell cancer.
Med Lett Drugs Ther; 2010 May; 52(1337):33-4. PubMed ID: 20431519
[No Abstract] [Full Text] [Related]
24. Posterior reversible encephalopathy syndrome induced by pazopanib for renal cell carcinoma.
Asaithambi G; Peters BR; Hurliman E; Moran BP; Khan AS; Taylor RA
J Clin Pharm Ther; 2013 Apr; 38(2):175-6. PubMed ID: 23210935
[TBL] [Abstract][Full Text] [Related]
25. Pazopanib: an orally administered multi-targeted tyrosine kinase inhibitor for locally advanced or metastatic renal cell carcinoma.
Koc G; Wang X; Luo Y
Can J Urol; 2011 Dec; 18(6):5991-7. PubMed ID: 22166325
[TBL] [Abstract][Full Text] [Related]
26. Successful re-administration of Pazopanib in a patient with metastatic renal cell carcinoma and a history of Pazopanib-induced nephrotic syndrome: a case report.
Jeon SY; Lee NR; Yim CY
BMC Nephrol; 2019 Jan; 20(1):1. PubMed ID: 30606155
[TBL] [Abstract][Full Text] [Related]
27. Case report of a long-surviving man with metastatic renal cell carcinoma treated with pazopanib.
Ratta R; Santini D
Tumori; 2014; 100(2):e59-62. PubMed ID: 24852879
[TBL] [Abstract][Full Text] [Related]
28. Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma.
Sonpavde G; Hutson TE; Sternberg CN
Expert Opin Investig Drugs; 2008 Feb; 17(2):253-61. PubMed ID: 18230058
[TBL] [Abstract][Full Text] [Related]
29. ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease.
Patard JJ; Pignot G; Escudier B; Eisen T; Bex A; Sternberg C; Rini B; Roigas J; Choueiri T; Bukowski R; Motzer R; Kirkali Z; Mulders P; Bellmunt J
Eur Urol; 2011 Oct; 60(4):684-90. PubMed ID: 21704448
[TBL] [Abstract][Full Text] [Related]
30. [Adjuvant AUO study of renal cell carcinoma after nephrectomy: randomized, double-blind, placebo-controlled phase III study (PROTECT - AN 30/10) to investigate the effectiveness and safety of pazopanib as adjuvant therapy in patients with localized or local advanced renal cell carcinoma after nephrectomy].
Rexer H
Urologe A; 2011 Apr; 50(4):489-92. PubMed ID: 21472622
[No Abstract] [Full Text] [Related]
31. [First-line therapy of advanced or metastasized renal cell carcinoma: phase III, open, randomized sequence study to examine efficacy and tolerance of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the first-line treatment of patients with advanced or metastasized renal cell carcinoma (SWITCH-2 - AN 33/11)].
Rexer H;
Urologe A; 2014 May; 53(5):735-8. PubMed ID: 24727992
[No Abstract] [Full Text] [Related]
32. Pazopanib in renal cell carcinoma.
Ward JE; Stadler WM
Clin Cancer Res; 2010 Dec; 16(24):5923-7. PubMed ID: 21059813
[TBL] [Abstract][Full Text] [Related]
33. Pazopanib Exposure Relationship with Clinical Efficacy and Safety in the Adjuvant Treatment of Advanced Renal Cell Carcinoma.
Sternberg CN; Donskov F; Haas NB; Doehn C; Russo P; Elmeliegy M; Baneyx G; Banerjee H; Aimone P; Motzer RJ
Clin Cancer Res; 2018 Jul; 24(13):3005-3013. PubMed ID: 29330204
[No Abstract] [Full Text] [Related]
34. Long-term response to pazopanib in an elderly man with mRCC. A case report.
D'Aniello C; Cavaliere C; Pisconti S; Facchini G
Tumori; 2014; 100(6):e305-8. PubMed ID: 25688517
[TBL] [Abstract][Full Text] [Related]
35. Pazopanib. Kidney cancer: many risks, but is there a benefit for patients?
Prescrire Int; 2011 Mar; 20(114):64-6. PubMed ID: 21648224
[TBL] [Abstract][Full Text] [Related]
36. [First-line therapy of advanced or metastasized renal cell cancer: open randomized phase III sequence study to examine the effectiveness and tolerance of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the first-line treatment of patients with advanced or metastasized renal cell cancer (SWITCH-2 - AN 33/11)].
Rexer H
Urologe A; 2012 May; 51(5):724-6. PubMed ID: 22576149
[No Abstract] [Full Text] [Related]
37. Interferon-related mental deterioration after craniotomy for removal of metastatic renal cancer.
Takahashi S; Yokoyama H; Yanai Y; Kurimoto M; Ohta N; Kitamura T
Int J Urol; 2006 Mar; 13(3):282-4. PubMed ID: 16643624
[TBL] [Abstract][Full Text] [Related]
38. Outcomes of patients with metastatic renal cell carcinoma treated with pazopanib in daily clinical practice: a single institution experience.
Ricotta R; Di Bella S
Tumori; 2014; 100(3):e87-91. PubMed ID: 25076258
[TBL] [Abstract][Full Text] [Related]
39. Is advanced renal cell carcinoma becoming a chronic disease?
Larkin J; Gore M
Lancet; 2010 Aug; 376(9741):574-5. PubMed ID: 20728740
[No Abstract] [Full Text] [Related]
40. Exceptional Response to Cabozantinib of Rapidly Evolving Brain Metastases of Renal Cell Carcinoma: A Case Report and Review of the Literature.
Ciccarese C; Iacovelli R; Mosillo C; Tortora G
Clin Genitourin Cancer; 2018 Oct; 16(5):e1069-e1071. PubMed ID: 30005936
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
